Additionally, pembrolizumab, an anti-PD1 (programmed death 1) agent, and the association of nivolumab (anti-PD1) plus ipilimumab (anti-CTLA-4) have been approved in the second-line treatment of HCC [104,105] (Figure 3). This evidence concerns the gene CTLA4 and hepatocellular carcinoma.